PV Bulletin

Calcifediol PSUSA: Maintenance of Marketing Authorisation (PSUSA/00000491/202506)

EMA completed PSUSA for calcifediol; outcome is maintenance of marketing authorisation.

Primary source: European Medicines Agency (EMA)

PV Impact Brief

MonitoringConfidence: high

What changed

EMA issued PSUSA outcome for calcifediol: regulatory outcome is maintenance of marketing authorisation.

Why it matters

The PSUSA outcome confirms that no significant new safety concerns were identified, and no changes to the benefit-risk balance are needed. However, MAHs should review the PSUSA assessment report for any specific recommendations.

Action needed

Review the PSUSA documents for calcifediol and ensure alignment with any PRAC recommendations if applicable.

Relevant for
Regulatory Intelligence LeadSignal Management Lead
Processes impacted
Signal ManagementLabeling
Owner

Regulatory Intelligence Lead

Review cadence

quarterly

Regulatory action details

Action type
PSUSA
Publication date
2026-06-05
Safety issue
Maintenance of the marketing authorisation after periodic safety review (PSUSA/00000491/202506).

Affected products

  • Calcifediol

PV internal implications

None specified beyond maintenance of current marketing authorisation.

View regulator source

Evidence and confidence

Confidence: highSource updated: Jun 5, 2026

Full briefing

Practical implication

Review the PSUSA documents for calcifediol and ensure alignment with any PRAC recommendations if applicable.

The EMA's PSUSA procedure for calcifediol (PSUSA/00000491/202506) concluded with maintenance of the marketing authorisation. No additional risk minimisation measures or labelling changes were specified.

What changed: EMA issued PSUSA outcome for calcifediol: regulatory outcome is maintenance of marketing authorisation.

Why it matters: The PSUSA outcome confirms that no significant new safety concerns were identified, and no changes to the benefit-risk balance are needed. However, MAHs should review the PSUSA assessment report for any specific recommendations.

Practical implication: Review the PSUSA documents for calcifediol and ensure alignment with any PRAC recommendations if applicable.

View original source

Published from the Firecrawl agent regulatory extraction pipeline.

#Safety Signals#firecrawl-agent#regulatory-extraction#Other#European Medicines Agency (EMA)#PSUSA

Related updates for your role

publicFDA · USA · Updated Sep 4, 2026

FDA Grants Accelerated Approval to Etcamah for Advanced Breast Cancer

Urgency: High

Regulatory teams must prepare for updating labeling to include details on the new indication and required diagnostic methods, along with planning for the confirmatory studies mandated by the FDA.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicMHRA · UK · Updated Sep 4, 2026

Change to the definition of regulated activity with children from 1 September 2026

Urgency: High

Organizations must re-evaluate roles related to children's activities and prepare to request Enhanced DBS checks including access to the Children’s Barred List check starting from 1 September 2026.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicUK Health Security Agency · UK · Updated Sep 7, 2026

Low Flu Vaccination Rates Among Primary School Children

Urgency: High

Parents are reminded to complete and return flu vaccination consent forms promptly as vaccination sessions in schools are set to start this week, aiming for completion by late November.

Signal ManagementPV Quality Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: PV Quality Lead, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Recall of Gore Viabahn Endoprosthesis with Bioactive Heparin Coating

Urgency: High

Health establishments receiving affected devices must be notified, and protocols established to ensure compliance with the recall.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward